anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The incidence for clinically relevant postoperative pancreatic fistulas (CR-POPF) in distal pancreatectomy (DP) ranges up to 25%. None of the available sealants significantly reduce CR-POPF. A new biodegradable sealant patch was able to reduce POPF and to achieve bleeding control in a preclinical porcine DP model. The aim of this first-in-human study was to assess the safety and performance of the sealant patch.
METHODS: In this multicenter, single-arm study, 40 patients undergoing distal pancreatectomy were prospectively enrolled from 8 centers. Following surgical resection, the transection plane was closed according to the standard of care and manually covered with the sealant patch. As primary endpoint the incidence of CR-POPF up to 30-days postoperatively was evaluated. The secondary endpoints included the assessment of complications and device usability.
RESULTS: Among 40 patients after distal pancreatectomy, CR-POPF occurred in 7 (17.5%) up to postoperative day 30. No type C POPF was observed. There was no intraoperative bleeding observed after patch application.
CONCLUSION: The results of this international phase II study demonstrate promising results of a new sealant patch regarding the rate of CR-POPF. Randomized studies are now needed to confirm the superiority of the current patch as compared to the best current practice.
Ranibizumab-naïve (Non-ANCHOR) patients received up to 12 intravitreal injections (Month 0 through Month 11). The dose of 0.3 mg ranibizumab was administered monthly for three consecutive months. From Month 3 through Month 11, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab were injected as individually needed based on re-treatment criteria described in the protocol. For patients who had participated in the ANCHOR study, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab was injected if the patient met re-treatment criteria described in the protocol. Ranibizumab was administered no sooner than 14 days after the previous treatment.
INTRODUCTION: Child stunting has a complex aetiology, especially in the first 1000 days of life. Nutrition interventions alone have not produced expected impacts in reducing/preventing child stunting, indicating the importance of understanding the complex interplay between environmental, physiological and psychological factors influencing child nutritional status. This study will investigate maternal and child nutrition, health and well-being status and associated factors through the assessment of: (1) anthropometry, (2) biomarkers of nutrition and health status, (3) dietary intakes, (4) fetal growth and development, (5) infant morbidity, (6) infant and young child feeding (IYCF) and (7) perinatal maternal stress, depression and social support.
METHODS: This study will be conducted in a prospective pregnancy cohort in India, Indonesia and Senegal. Pregnant women will be recruited in the second (Indonesia, Senegal) and third (India) trimester of pregnancy, and the mother and infant dyads followed until the infant is 24 months of age. During pregnancy, anthropometric measures will be taken, venous blood samples will be collected for biochemical assessment of nutrition and health status, dietary intakes will be assessed using a 4-pass-24-hour dietary recall method (MP24HR), fetal ultrasound for assessment of fetal growth. After birth, anthropometry measurements will be taken, venous blood samples will be collected, MP24HR will be conducted, infant morbidity and IYCF practices will be assessed and a sample of breastmilk will be collected for nutrient composition analyses. Perinatal maternal stress, depression, social support and hair cortisol levels (stress) will be measured. The results from this study will be integrated in an interdisciplinary analysis to examine factors influencing infant growth and inform global efforts in reducing child stunting.
ETHICS AND DISSEMINATION: Ethical approval was granted by the Ethics Committee of the London School of Hygiene and Tropical Medicine (17915/RR/17513); National Institute of Nutrition (ICMR)-Ministry of Health and Family Welfare, Government of India (CR/04/I/2021); Health Research Ethics Committee, University of Indonesia and Cipto Mangunkusumo Hospital (KET-887/UN2.F1/ETIK/PPM.00.02/2019); and the Comité National d'Ethique pour la Recherche en Santé, Senegal (Protocole SEN19/78); the Royal Veterinary College (URN SR2020-0197) and the International Livestock Research Institute Institutional Research Ethics Committee (ILRI-IREC2020-33). Results will be published in peer-reviewed journals and disseminated to policy-makers and participating communities.
BACKGROUND: Functional dyspepsia is a disorder of gut-brain interaction that has the potential to impact aviation performance. Proton pump inhibitors are well-tolerated but are only effective in one half of cases. Second-line treatments, including tricyclic antidepressants, are associated with drowsiness and are not routinely approved for use in aviators. We present a case of a Naval Flight Officer with functional dyspepsia who was successfully treated with amitriptyline and returned to flying status.CASE REPORT: A 23-yr-old male Naval Flight Officer presented with postprandial fullness and epigastric pain. His symptoms were refractory to trials of acid suppression and lifestyle modification. An extensive evaluation by Gastroenterology, including upper endoscopy, did not reveal an organic cause of his symptoms and he was diagnosed with functional dyspepsia. The patient's symptoms resolved with a trial of amitriptyline. Neuropsychological testing demonstrated no medication effect on cognitive performance. A waiver to resume flying duties on amitriptyline was submitted to the Naval Aerospace Medical Institute and was approved.DISCUSSION: We present the second known waiver issued in U.S. Naval aviation history for the use of amitriptyline to treat a gastrointestinal disorder. Amitriptyline is not commonly waived due to the potential for unacceptable cognitive side-effects in the flight environment. However, neuropsychological testing to assess for a possible medication effect on performance can be used to inform an aeromedical disposition and, in this case, allowed for a return to flight status.Crutcher R, Kolasinski N. Functional dyspepsia and tricyclic antidepressant use in a naval flight officer. Aerosp Med Hum Perform. 2024; 95(6):337-340.
COVID-19 patients who survived on the 28th day in hospital belong to survivors group. In the survivors group, we included 201 patients with complete data.
Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. Subjects are instructed to exercise 30 minutes on an exercise bicycle, achieving at heart rate of approximately 108 bpm. Exercise is performed after 2.5 hours, 5.5 hours, and 8.5 hours after topical system application.
Aortic valve reconstruction using autologus pericardium (Ozaki procedure). The autologous pericardium is harvested after routine median sternotomy. Harvested pericardium is then treated with a 0.6% glutaraldehyde solution for 10 min and then rinsed 3 times with sterilized saline each time for 6 min. After resection of the diseased aortic valve cusps, the distance between each commissure is measured using a self-developed sizing instrument. Glutaraldehyde-treated autologous pericardium is trimmed with a self-developed template corresponding to the measured value. The annular margin of the pericardial leaflet is then running-sutured to each annulus with 3-0 monofilament sutures. Commissural coaptation is secured with additional 4-0 monofilament sutures. The coaptation of the 3 cusps is then checked with negative pressure on the left ventricular vent.
Head and neck cancer (HNC) is the 6th most common type of cancer in the world and has recently seen a dramatic rise in the United States due to a rise in the incidence of oropharyngeal cancers related to the human papillomavirus (HPV) . The majority of patients diagnosed with HNC receive radiation therapy at some point in their treatment, either in the definitive or post-operative setting. Dysphagia is a common consequence of treatment for HNC, experienced by approximately 50% of patients treated with radiation therapy. Post-treatment dysphagia has been associated with increased risk of morbidity/mortality as well as well-recognized deterioration of quality of life. Performance of swallowing exercises during radiation significantly reduces dysphagia risk; however, patient adherence to swallowing exercises during radiation treatment is limited. Thus, poor adherence stands as a major obstacle to achieving the best swallowing outcomes. In response to this, a mobile health application was developed to directly address barriers cited by patients as reasons for non-adherence. The objective is to conduct a randomized controlled trial to test the impact of the mobile application on adherence to prophylactic swallowing therapy during radiation for HNC.
The invention relates to a process for producing a ceramic network material from a ceramic suspension by casting said suspension in a tooth-shaped mold. The suspension includes dispersed alumina particles in a medium containing deionized water with a pH in a range of about 4 to 5 and a concentration of polyvinyl alcohol in a range of about 0.5 to 1% by weight. The process includes the steps of slip casting the suspension in a plaster tooth mold and drying the molded suspension to draw the water from the suspension. The dried suspension then is fired in a furnace at a temperature in a range of about 1000 to 1400  DEG C to form a ceramic network. After the dried suspension has been fired and excess water and polyvinyl alcohol has been removed from the suspension, lanthanum aluminosilicate glass is infused to a coronal portion of the ceramic network to form a glass layer with a thickness in a range of about 1 to 2 mm within the ceramic network. A monomer, such as a monomer solution, then is infused to at least the portion of the ceramic network within the glass layer. Alternatively, the ceramic network may be infused with a metal alloy to form a layer on the coronal portion or with one or more monomers. <IMAGE>
The present invention relates to a composition for inhibiting formation of a SNARE complex, which comprises a myricetin derivative. According to the present invention, not only laricitrin, combretol and syringetin, each of which is one of myricetin derivatives, but also a myricetin derivative having a novel structure obtained by acylation of myricetin can inhibit formation of a SNARE complex in vivo. Thus, it is possible to provide a composition for inhibiting formation of a SNARE complex using the derivatives as SNARE-targeted prodrugs. After carrying out investigation, it is thought that myricetin derivatives are biologically converted into myricetin in cells to provide the effect. The myricetin derivatives have no dark color of the existing myricetin and undergo a change in properties to have photo-stability and oil solubility. Therefore, stable forms of myricetin derivatives are absorbed into cells to show an ability of inhibiting formation of a SNARE complex provided by the original myricetin. As a result, the myricetin derivatives can be used as SNARE-targeted prodrugs and can provide a composition for inhibiting formation of a SNARE complex comprising the same.
Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . For patients with co-morbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
All participants allocated to the standard of care arm will receive all RT treatment activities according to institutional standards. Participants will attend the weekly in-person review session with a Radiation Oncologist during treatment and will be seen once between 4 and 12 weeks after last RT treatment. Documentation of radiation-related toxicity will be performed by the radiation HCPs according to standard of care. Participants will be asked to complete the following study questionnaires: 1) Baseline evaluation (patient factors); 2) 'During treatment' evaluation (need/usefulness of review); 3) 'Post acute phase' evaluation (satisfaction with care).
A method for identifying highly-skewed classes using an imperfect annotation of every instance together with a set of features for all instances. The imperfect annotations designate a plurality of instances as belonging to the target rare class and others to the majority class. First, a classifier is trained on the set of features using the imperfect annotation as supervision, to designate each instance to either the rare class or majority class. A combination of the predictions from the trained classifier and the imperfect annotations is then used to classify each instance to either the rare class or majority class. In particular, an instance is classified to the rare class only when both the trained classifier and the imperfect annotation classify the instance to the rare class. Finally, for each instance assigned as a rare class instance by the combination stage, all instances in its neighborhood are re-classified as either rare class or majority class.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as tolmetin sodium tablets. Some of these events have been fatal or life-threatening. DRESS typically, although not  
exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue tolmetin sodium tablets and evaluate the patient immediately.
The symptoms associated with benign prostatic hyperplasia (BPH), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component of BPH is associated with an increase in smooth muscle tone in the prostate and bladder neck. The degree of tone in this area is mediated by the alpha1 adrenoceptor, which is present in high density in the prostatic stroma, prostatic capsule, and bladder neck. Blockade of the alpha1 receptor decreases urethral resistance and may relieve the BPH symptoms and improve urine flow. Doxazosin mesylate is a selective inhibitor of the alpha1-subtype of alpha adrenergic receptors. In the human prostate, doxazosin mesylate antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1A adrenoceptor.
A monitoring device for monitoring the physiological condition of a patient ( 1 ) on a continuous basis, which includes a transmitter unit ( 2 ) adapted to attach to a patient so as to be in contact with the skin of a patient, a corresponding receiver unit ( 5 ). The transmitter unit includes a strap or belt ( 3 ) adapted to attach to or around a body part of a patient. A plurality of sensors (E) are mounted to the belt for monitoring a plurality of patient physiological parameters, including at least the patient's skin impedance, heart rate and aspects of the heart beat. The sensors are connected to a microcontroller ( 8 ) which processes the signals and which is linked to a wireless transmitter ( 9 ). A portable receiver unit is adapted to receive and process the signal from the transmitter. The receiver unit includes a display ( 14 ) for data relating to the patient and preferably an alarm ( 15 ).
This study will consist of 52-week treatment period and a 4-week follow-up period. 52-week treatment period comprises of a 26-week treatment period A (Day 0 to Day 182) and a 26-week treatment period B (Day 183 to Day 364). Participants who complete treatment period A will immediately continue into treatment period B. After completion of treatment period B participants may roll over into an expanded access study TAK-743-5007 (NCT04687137). Participants who elect to rollover to Study TAK-743-5007 will complete their end of study (EOS) assessments on Day 378. All other participants will complete their EOS assessments on Day 392.
Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. The type and dose of progestogen may be important. Nonhormonal causes should be considered and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding, as in the case of any abnormal vaginal bleeding. If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of amenorrhea, pregnancy should be ruled out. Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent.
1,223,250. Two-component packs for hair treatment. L'OREAL. 19 April, 1967 [19 April, 1966], No. 2326/70. Divided out of 1,197,031. Addition to 1,197,037. Heading DIP. A two-component pack for use in the treatment of hair comprises, as the first component, a methylolated compound which is monomethylol dicyandiamide, bis-methoxymethyl urea, monomethylol dimethylhydantoin, monomethylol ethyleneurea, monomethylol ethylene thiourea, dimethylol ethylene thiourea. monomethylol guanidine, monomethylol ethyl carbamate. N, N'-dimethylol (2-methyl- 2-propyl) propylene bis-carbamate, dimethylol ethyl methylene-bis-carbamate, dimethylol succinamide, dimethylol adipamide. N, N-diethyl-N'-methylol urea, dimethylol ethylene urea, dimethylol ethyl carbamate or tetramethylol acetylene diurea in the solid state, and, as the second component, an acid polymerisation catalyst, either or both of these components containing a solution a nitrogencontaining compound which is urea, melamine, dicyandiamide, N, N-diethyl urea, ethylene urea, isopropyl carbamate, dimethyl hydantoin, ethylene thiourea, guanidine carbamate or succinamide, or comprises, as the first component, a methylolated compound which is monomethylol urea, dimethylol urea, monomethylol thiourea, dimethylol thiourea or trimethylol melamine in the solid state, and, as the second component, an acid polymerisation catalyst, either or both of these components containing a solution of a nitrogen-containing compound which is N, N-diethylurea, ethylene urea. isopropyl carbamate, dimethyl hydantoin. ethylene thiourea or succinamide, the relative proportions of the active ingredients in the components being such that on mixing the entire contents of the two components a composition containing 0.5-12% by weight of the methylolated compound is obtained. The number of amino groups provided by the nitrogen containing compound may be 0.1-1 times the number of methylolated groups provided by the methylolated compound. The amount of acid polymerisation catalyst, e.g. acetic, citric, lactic, phosphoric or sulphuric acid or sodium acid phosphates, may be such that the resulting composition has a  # H of 1.5-3. The resulting composition may be in the form of a hair setting lotion.
Subjects will be randomized at enrollment into either a delayed or immediate continuation group. The immediate continuation group will immediately continue with the stimulation after a 30-day trial period and will be monitored for a total of 12 months. The delayed activation group will have their device turned off after the 30-day trial period for the next 3-months. At the 3-month visit, both groups be evaluated and the delayed activation group will have their devices reactivated.

Subjects will have neuropathic pain of various etiologies, including trauma, surgery or post-herpetic infections. Stimulators will be placed at the site target of the painful area, including the epifascial plane under the skin but above the muscles in the vicinity of the targeted branches of; A. Branches of Trigeminal Nerves in the Ophthalmic, Maxillary, or Mandibular B. Sensory branches of Facial Nerves C. Branches of the Occipital Nerves (Greater and/or Lesser) D. Branches of the Cervical Plexus (Superficial and/or Deep)
BACKGROUND: Coronary artery dissection is managed primarily conservatively with serial imaging or percutaneous coronary intervention (PCI). Exposure to contrast in either modality could potentially result in acute tubular necrosis (ATN). However, no data compares ATN incidence in these management strategies. This study compares the incidence of ATN and associated mortality of PCI and conservative management of coronary artery dissection.
METHODS: A retrospective analysis was performed using data from the National Inpatient Sample database, including patients with coronary artery dissection between 2016 through 2020. We analyzed the incidence of ATN and associated mortality of PCI and conservative management of coronary artery dissection.
RESULTS: We found that the odds of developing ATN were 22% lower in patients managed with PCI than those managed conservatively. There was no difference in the in-hospital mortality or hospital length of stay between the two groups but the mortality rate in patients with ATN was double that of those who did not develop ATN in both PCI and conservatively managed groups.
CONCLUSIONS: The higher incidents of ATN in patients with coronary dissection being managed with conservative measures compared to PCI suggest that the use of CTA may be harmful. Additionally, persons who developed ATN may have higher mortality. Therefore, more studies in the management of coronary artery dissection need to be done which would allow further steps to be taken to reduce this harm.
PROBLEM TO BE SOLVED: To provide an aromatic device for personal belongings, which allows exchange of an aromatic material without inconvenience, and especially facilitates detachment and attachment of a cover and the aromatic material to and from personal belonging main body. SOLUTION: The aromatic device is formed of the personal belonging main body, the cover, and the aromatic material sealed in the main body by the cover, which each are made of a non-magnetic material. The personal belonging main body has a cavity which has a stepped surface for accommodating the cover, on an inner peripheral portion thereof. Further, the main body has a projection from a bottom surface of the cavity at a central portion of the same, which projection functions as a fitting portion of the aromatic material. The main body also has a nail hooking port at a cover fitting edge, for detaching the cover from the main body. Then, a plurality of magnets which are attractive to each other are fitted to the cover fitting edge of the main body and an inner peripheral edge of the cover, at equally separated locations.  In addition, the cover has a vent hole formed therein, for releasing an aroma from the aromatic material.